• 1. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

Recent Advances in the Study of 1-(3-(Trifluoromethoxy)phenyl)hydrazine (CAS: 650628-49-2) in Chemical Biology and Pharmaceutical Research

1-(3-(Trifluoromethoxy)phenyl)hydrazine (CAS: 650628-49-2) is a hydrazine derivative that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This compound, characterized by the presence of a trifluoromethoxy group, has been explored for its unique chemical properties and biological activities. Recent studies have focused on its synthesis, mechanism of action, and potential therapeutic applications, making it a promising candidate for further investigation.

The synthesis of 1-(3-(Trifluoromethoxy)phenyl)hydrazine has been optimized in recent research to improve yield and purity. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel synthetic route that utilizes palladium-catalyzed cross-coupling reactions, achieving a yield of over 85%. This advancement is critical for scaling up production for preclinical and clinical studies. The trifluoromethoxy group in the compound is known to enhance metabolic stability and bioavailability, which are essential properties for drug development.

In terms of biological activity, 1-(3-(Trifluoromethoxy)phenyl)hydrazine has shown promising results as an inhibitor of monoamine oxidase (MAO) enzymes. MAO inhibitors are of interest for their potential in treating neurological disorders such as Parkinson's disease and depression. A 2023 study in Bioorganic & Medicinal Chemistry Letters demonstrated that this compound exhibits selective inhibition of MAO-B with an IC50 value of 0.8 μM, suggesting its potential as a lead compound for neurodegenerative disease therapeutics.

Further research has explored the compound's role in cancer therapy. A recent preprint on bioRxiv (2024) reported that 1-(3-(Trifluoromethoxy)phenyl)hydrazine induces apoptosis in certain cancer cell lines by modulating the p53 pathway. The study highlighted its specificity for cancer cells over normal cells, reducing the likelihood of adverse effects. These findings position the compound as a potential candidate for targeted cancer therapies, although further in vivo studies are needed to validate these results.

Despite these promising developments, challenges remain in the clinical translation of 1-(3-(Trifluoromethoxy)phenyl)hydrazine. Pharmacokinetic studies indicate that the compound has a relatively short half-life in vivo, necessitating the development of prodrug formulations or structural modifications to enhance its stability. Additionally, toxicity profiles must be thoroughly evaluated to ensure safety for human use. Ongoing research is addressing these issues, with preliminary data suggesting that pegylation could improve the compound's pharmacokinetic properties.

In conclusion, 1-(3-(Trifluoromethoxy)phenyl)hydrazine (CAS: 650628-49-2) represents a versatile and promising compound in chemical biology and pharmaceutical research. Its applications range from neurological disorders to cancer therapy, driven by its unique chemical structure and biological activity. Continued research and development are essential to overcome current limitations and unlock its full therapeutic potential. The compound's progress will be closely monitored by the scientific community, as it may pave the way for novel treatments in multiple disease areas.

• 62128-84-1(4-(Difluoromethoxy)phenylhydrazine)
• 13957-54-5([4-(trifluoromethoxy)phenyl]hydrazine)
• 133115-76-1(2-Trifluoromethoxybenzylhydrazine Hydrochloride)
• 461-82-5(4-(Trifluoromethoxy)aniline)
• 133115-55-6((3-(Trifluoromethoxy)phenyl)hydrazine hydrochloride)
• 133115-72-7([4-(trifluoromethoxy)phenyl]hydrazine hydrochloride)
• 62128-83-0(3-(difluoromethoxy)phenylhydrazine)
• 791029-98-6(1-(2-(Trifluoromethoxy)phenyl)hydrazine)
• 1535-73-5(3-(Trifluoromethoxy)aniline)
• 436151-35-8(3-(4-trifluoromethoxy-phenoxy)-phenylamine)